UPDATE SEPT 2015: The UNC Vector Core (small scale research grade group only) will be moving to a new location on 9/29/15. Orders may be delayed around this time, please plan accordingly. Thanks!
The Vector Core at the University of North Carolina at Chapel Hill (UNC Vector Core) was founded in 1993 as a full-service viral vector production organization. We have extensive experience in vector design, process development, as well as manufacturing of research and clinical grade vectors and we utilize our unique expertise to ensure your project is on time and on budget.
Our goal is to deliver the highest quality vectors to our academic, government, foundation, and biotech industry clients. We also offer process development, assay development, and other support services to accelerate the research and development process.
New 11,000 sq. ft. Production Facility
The Vector Core has recently relocated to a new state-of-the-art manufacturing site between the campus of UNC and Research Triangle Park (RTP). The facility occupies an area of over 11,000 square feet and was specifically designed and constructed for the production of research, preclinical, and clinical grade viral vectors. The space includes separate suites for non-viral work, different viruses, quality control, process development, and support areas.
The manufacturing and testing of clinical grade materials occurs in the 3000 ft2 Human Application Lab (HAL). The HAL includes ISO 7 cleanrooms with 3 modules for concurrent production of different vectors, a non-viral module, and a storage/prep area. In addition, there is an ISO 6 suite dedicated for sterile fill and finish. The HAL production area utilizes unidirectional flow of materials and personnel, separate air handlers, and a Rees monitoring system.
Our Production Platform
We have developed a suspension cell based production platform that utilizes serum-free media to increase efficiency and purity. Our proprietary system decreases the amount of processing steps necessary in methods using adherent cells while also reducing the variability and shortcomings associated with using FBS, giving our clients superior vectors at a lower cost.
Our system is easily scalable from 500mL to multiple 20L bioreactor batch sizes. This uniform manufacturing structure ensures the consistency of our vectors across multiple production scales. So, whether you need a small amount of virus for in vitro analysis of your gene of interest or large scale vector production for clinical applications, you can be sure that your material will be of the highest quality and perform as expected.
The absence of animal components in the manufacturing of our clinical grade vectors reduces the risk of contamination from adventitious agents. In addition, our production platform uses Wave bioreactors to minimize the number of open steps and cross-contamination, providing safer clinical materials and less regulatory hurdles.